Drug Trial Radar · NCT05307328
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Sep 1, 2022
Primary completion
Aug 1, 2025
Study completion Aug 1, 2025
Sponsor
- Lead sponsor
- Sparrow PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor. Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.
Conditions
- Cushing's Syndrome I
- Cushing Disease Due to Increased ACTH Secretion
- Cortisol Excess
- Cortisol; Hypersecretion
- Cortisol Overproduction
- Ectopic ACTH Secretion
Interventions
SPI-62Drug
11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
PlaceboDrug
Inactive tablets identical to SPI-62 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in urinary HSD-1 ratioTime frame: Baseline to 6 weeks
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
St. Joseph's Hospital and Medical Center - Barrow Neurological Institute (BNI) - Pituitary Center
Phoenix, Arizona
Southwest General Healthcare Center
Fort Myers, Florida
Mayo Clinic Cancer Center (MCCC) - Rochester
Rochester, Minnesota
Washington University School of Medicine - Center for Advanced Medicine (CAM)
St Louis, Missouri
Comprehensive and Interventional Pain Management Llp
Henderson, Nevada
Memorial Sloan-Kettering Cancer Center
New York, New York
Oregon Health & Science University (OHSU) - Northwest Pituitary Center
Portland, Oregon
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Medical University of Plovdiv
Plovdiv, Bulgaria
Clinical Center of Endocrinology and Gerontology, University Hospital of Endocrinology, Medical University Sofia (USHATE)
Sofia, Bulgaria
Medical University of Sofia
Sofia, Bulgaria
Carol Davila University of Medicine and Pharmacy
Bucharest, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.